Tumor News and Research

RSS

New study suggests novel ways to treat serous retinal detachment

Wet age-related macular degeneration (AMD) is the leading cause of severe vision loss in older individuals. AMD and other serious chronic eye problems that affect younger individuals result when fluid accumulates abnormally under or within the retina. A new study published in The American Journal of Pathology shows for the first time that the release of substances from mast cells may be a causal factor in this type of eye pathology, and inhibitors of this release may offer new ways to treat serous retinal detachment.

22 Jul 2015

New genomic fingerprint may predict prostate cancer risk in African American men

African American men are more likely to develop prostate cancer than European American men, and are also more than twice as likely to die from it. Although there are many reasons that contribute to this health disparity, new research shows that African American men may have a distinctly different type of prostate cancer than European American men, according to new genomic fingerprinting results.

21 Jul 2015

UCLA scientists identify new method to deliver glucose to pancreatic and prostate cancer cells

UCLA scientists have for the first time identified a new sodium-dependent mechanism to deliver glucose—the body's main fuel that drives tumor growth—to pancreatic and prostate cancer cells, offering new hope in the fight against two of the deadliest forms of the disease.

21 Jul 2015

MD Anderson researchers find high prevalence of hereditary CRC among people diagnosed before the age of 35

Hereditary colorectal cancers, caused by inherited gene mutations, are relatively rare for most patients. However, researchers at The University of Texas MD Anderson Cancer Center have discovered a particularly high prevalence of hereditary cancers among those diagnosed with the disease before the age of 35. They suggest that these patients should undergo genetic counseling to determine if their families may be at an elevated risk.

21 Jul 2015

Patients' own genetically engineered immune cells show significant success against multiple myeloma

In recent years, immunotherapy has emerged as a promising treatment for certain cancers. Now this strategy, which uses patients' own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.

21 Jul 2015

Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announced today that the U.S. Food and Drug Administration Office of Orphan Products Development has granted Orphan Drug Designation for melphalan for the treatment of cholangiocarcinoma.

20 Jul 2015

NeoGenomics announces launch of new germline cancer predisposition testing services

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new tests include comprehensive testing for BRCA1 and BRCA2 encompassing an analysis of all exons and adjacent intronic regions.

20 Jul 2015

Alternative limb-lengthening technique makes recovery process less cumbersome

A highly specialized procedure that lengthens bones can prevent the need for amputations in selected patients who have suffered severe fractures.

20 Jul 2015

New approach to imaging glucose uptake activity in single living cells

Researchers at Columbia University have reported a new approach to visualize glucose uptake activity in single living cells by light microscopy with minimum disturbance. In a recent study published in Angewandte Chemie International Edition, Associate Professor of Chemistry Wei Min's team developed a new glucose analogue that can mimic the natural glucose, and imaged its uptake as energy source by living cancer cells, neurons and tissues at the single cell level.

20 Jul 2015

UofL conducts Phase I research study for children with relapsed tumors

Zach feels "pretty good." Sam wants to be "done with shots!" And Tyler finds it helps to "just keep thinking that at least I'm getting out of school." They are normal boys who had normal lives until cancer came into the picture. All have faced the disease for two years or more, with surgeries, chemotherapy and radiation treatments. All were diagnosed with various malignant solid tumors, went into remission and then relapsed.

17 Jul 2015

BUSM investigators receive MRA's Jackie King Young Investigator Awards

Boston University School of Medicine researchers Neil Joseph Ganem, PhD and Anurag Singh, PhD, each have received the Jackie King Young Investigator Awards from the Melanoma Research Alliance (MRA), the largest private funder of melanoma research. Both serve as assistant professors of pharmacology & experimental therapeutics and medicine.

17 Jul 2015

Increased radiation dose offers survival benefit for men with medium- and high-risk prostate cancer

Increased radiation dose is associated with higher survival rates in men with medium- and high-risk prostate cancer, but not men with low-risk prostate cancer, according to a new study from Penn Medicine published this week in JAMA Oncology. Already-high survival rates for men with low-risk prostate cancer were unaffected by higher radiation dosages compared to lower radiation dosages.

17 Jul 2015

Genetic mutation associated with severe loss of body fat, appearance of premature aging in children identified

Researchers at the Translational Genomics Research Institute have identified a genetic mutation associated with the appearance of premature aging and severe loss of body fat in children.

17 Jul 2015

Study shows that 14-3-3 sigma opposes, reverses tumor-promoting metabolic programs

Every parent knows the maxim "feed a cold, starve a fever." In cancer, however, exactly how to feed or starve a tumor has not been easy to determine.

16 Jul 2015

New treatment improves outcome for early FDG-PET-positive patients with stages I/II Hodgkin lymphoma

Final results of the randomized intergroup EORTC, LYSA (Lymphoma Study Association), FIL (Fondazione Italiana Linfomi) H10 trial presented at the 13th International Conference on Malignant Lymphoma in Lugano, Switzerland, on 19 June 2015 show that early FDG-PET ( 2-deoxy-2[F-18]fluoro-D-glucose positron emission tomography) adapted treatment improves the outcome of early FDG-PET-positive patients with stages I/II Hodgkin lymphoma.

16 Jul 2015

Magnetic nanoparticles may hold key to bringing immunotherapy into successful clinical use

In recent years, researchers have hotly pursued immunotherapy, a promising form of treatment that relies on harnessing and training the body's own immune system to better fight cancer and infection. Now, results of a study led by Johns Hopkins investigators suggests that a device composed of a magnetic column paired with custom-made magnetic nanoparticles may hold a key to bringing immunotherapy into widespread and successful clinical use.

16 Jul 2015

Two chemical compounds effectively inhibit growth of brain cancer cells and breast tumors

Researchers have discovered two chemical compounds that effectively stop the growth of brain cancer cells and breast tumors, opening the way for potential new drugs to be developed.

16 Jul 2015

Apogenix signs licensing agreement with CANbridge to commercialize APG101 in China, Macao and Hong Kong

Apogenix, a next generation immuno-oncology company, announced today that it has entered into an exclusive licensing agreement with CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, for the development and commercialization of lead immuno-oncology drug candidate APG101 in China, Macao, and Hong Kong.

15 Jul 2015

Study examines how low-methionine diet may help improve outcomes in triple-negative breast cancer patients

A diet that starves triple-negative breast cancer cells of an essential nutrient primes the cancer cells to be more easily killed by a targeted antibody treatment, UW Carbone Cancer Center scientists report in a recent publication.

15 Jul 2015

Accuray announces presentation of CyberKnife System data at AAPM annual meeting

Accuray Incorporated announced today that studies on the clinical use of the CyberKnife System, the only robotic SBRT system capable of tracking and automatically correcting for target motion, continue to demonstrate the benefits of its precise, innovative treatment delivery techniques.

14 Jul 2015

Tumor News and Research

New study suggests novel ways to treat serous retinal detachment

New genomic fingerprint may predict prostate cancer risk in African American men

UCLA scientists identify new method to deliver glucose to pancreatic and prostate cancer cells

MD Anderson researchers find high prevalence of hereditary CRC among people diagnosed before the age of 35

Patients' own genetically engineered immune cells show significant success against multiple myeloma

Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma

NeoGenomics announces launch of new germline cancer predisposition testing services

Alternative limb-lengthening technique makes recovery process less cumbersome

New approach to imaging glucose uptake activity in single living cells

UofL conducts Phase I research study for children with relapsed tumors

BUSM investigators receive MRA's Jackie King Young Investigator Awards

Increased radiation dose offers survival benefit for men with medium- and high-risk prostate cancer

Genetic mutation associated with severe loss of body fat, appearance of premature aging in children identified

Study shows that 14-3-3 sigma opposes, reverses tumor-promoting metabolic programs

New treatment improves outcome for early FDG-PET-positive patients with stages I/II Hodgkin lymphoma

Magnetic nanoparticles may hold key to bringing immunotherapy into successful clinical use

Two chemical compounds effectively inhibit growth of brain cancer cells and breast tumors

Apogenix signs licensing agreement with CANbridge to commercialize APG101 in China, Macao and Hong Kong

Study examines how low-methionine diet may help improve outcomes in triple-negative breast cancer patients

Accuray announces presentation of CyberKnife System data at AAPM annual meeting

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News